3D-printed individual template brachytherapy for the treatment of intractable central pelvic recurrent cervical cancer: A single institution experience

IF 1.7 4区医学 Q4 ONCOLOGY

Brachytherapy Pub Date : 2024-11-01 DOI:10.1016/j.brachy.2024.05.004

Xiaolu Zhu , Manting Zeng , Youyi Dai , Weilu Kuang , Zijian Zhang , Shan Li , Hong Zhu

{"title":"3D-printed individual template brachytherapy for the treatment of intractable central pelvic recurrent cervical cancer: A single institution experience","authors":"Xiaolu Zhu , Manting Zeng , Youyi Dai , Weilu Kuang , Zijian Zhang , Shan Li , Hong Zhu","doi":"10.1016/j.brachy.2024.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>OBJECTIVE</h3><div>The prognosis of recurrent cervical cancer tends to be poor and there are limited effective treatments currently available for these patients. This study was developed to find a safe and effective treatment for patients with central pelvic recurrent cervical cancer.</div></div><div><h3>MATERIALS AND METHODS</h3><div>This retrospective study analyzed patients with central pelvic recurrent cervical cancer who received 3D-printed individual template (3D-PIT) brachytherapy between February 2019 and June 2023. Analyses of dosimetric parameters, toxicity-related complications, and survival were conducted based on the data of these patients.</div></div><div><h3>RESULTS</h3><div>Twenty-one patients with central pelvic recurrent cervical cancer patients were enrolled. All of them received 3D-printed individual template (3D-PIT) brachytherapy. The mean respective adjusted cumulative HRCTV-D90 and HRCTV-D98 values for these patients were 86.9 Gy and 75.4 Gy. And the local control (LC) rate of these patients was 57.1%. In these 21 patients, only 2 (9.5%) of them experienced grade 3–4 rectal adverse reactions, while 7 (33.3%) patients experienced grade 3–4 bladder adverse reactions. 5(23.8%) patients had fistula, while 3 of these 5 patients had undergone prior anti-VEGF targeted drug treatment which is a risk factor of fistula. The respective 2-year rates of overall and progression-free survival (OS and PFS) for these patients were 72.9% and 57.4%, with a 26-month median PFS.</div></div><div><h3>CONCLUSIONS</h3><div>These single-institution data highlight the potential viability of 3D-PIT brachytherapy as an approach to managing intractable central pelvic recurrent cervical cancer following first-line treatment.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"23 6","pages":"Pages 634-640"},"PeriodicalIF":1.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124000722","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

OBJECTIVE

The prognosis of recurrent cervical cancer tends to be poor and there are limited effective treatments currently available for these patients. This study was developed to find a safe and effective treatment for patients with central pelvic recurrent cervical cancer.

MATERIALS AND METHODS

This retrospective study analyzed patients with central pelvic recurrent cervical cancer who received 3D-printed individual template (3D-PIT) brachytherapy between February 2019 and June 2023. Analyses of dosimetric parameters, toxicity-related complications, and survival were conducted based on the data of these patients.

RESULTS

Twenty-one patients with central pelvic recurrent cervical cancer patients were enrolled. All of them received 3D-printed individual template (3D-PIT) brachytherapy. The mean respective adjusted cumulative HRCTV-D90 and HRCTV-D98 values for these patients were 86.9 Gy and 75.4 Gy. And the local control (LC) rate of these patients was 57.1%. In these 21 patients, only 2 (9.5%) of them experienced grade 3–4 rectal adverse reactions, while 7 (33.3%) patients experienced grade 3–4 bladder adverse reactions. 5(23.8%) patients had fistula, while 3 of these 5 patients had undergone prior anti-VEGF targeted drug treatment which is a risk factor of fistula. The respective 2-year rates of overall and progression-free survival (OS and PFS) for these patients were 72.9% and 57.4%, with a 26-month median PFS.

CONCLUSIONS

These single-institution data highlight the potential viability of 3D-PIT brachytherapy as an approach to managing intractable central pelvic recurrent cervical cancer following first-line treatment.

查看原文本刊更多论文

用于治疗难治性中央盆腔复发性宫颈癌的 3D 打印个体模板近距离放射治疗：单一机构的经验。

目的：复发性宫颈癌的预后往往较差，目前可用于这些患者的有效治疗方法有限。本研究旨在为中央盆腔复发性宫颈癌患者找到一种安全有效的治疗方法：这项回顾性研究分析了2019年2月至2023年6月期间接受3D打印个体模板（3D-PIT）近距离治疗的中央盆腔复发性宫颈癌患者。根据这些患者的数据对剂量参数、毒性相关并发症和生存期进行了分析：21名中央盆腔复发性宫颈癌患者入选。所有患者都接受了三维打印个体模板（3D-PIT）近距离放射治疗。这些患者的调整后累积 HRCTV-D90 和 HRCTV-D98 的平均值分别为 86.9 Gy 和 75.4 Gy。这些患者的局部控制率（LC）为 57.1%。在这 21 例患者中，只有 2 例（9.5%）出现了 3-4 级直肠不良反应，7 例（33.3%）出现了 3-4 级膀胱不良反应。5例（23.8%）患者出现了瘘管，而这5例患者中有3例之前接受过抗血管内皮生长因子靶向药物治疗，这是瘘管的一个风险因素。这些患者的2年总生存率和无进展生存率（OS和PFS）分别为72.9%和57.4%，中位PFS为26个月：这些单个机构的数据突出表明，3D-PIT近距离放射治疗是治疗一线治疗后难治性盆腔中心复发性宫颈癌的一种潜在可行方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brachytherapy 医学-核医学

CiteScore

3.40

自引率

21.10%

发文量

119

审稿时长

9.1 weeks

期刊介绍： Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial and intracavitary radiation in the management of cancers. Laboratory and experimental research relevant to clinical practice is also included. Related disciplines include medical physics, medical oncology, and radiation oncology and radiology. Brachytherapy publishes technical advances, original articles, reviews, and point/counterpoint on controversial issues. Original articles that address any aspect of brachytherapy are invited. Letters to the Editor-in-Chief are encouraged.